Romahduksen syitä

Faronin tiedote 

https://faron.com/releases-and-publications/holding-in-company/  

A&B (HK) Company Ltd (“A&B”) on myynyt koko omistuksensa Faronissa; syy on päätuotekehityksen muutos 'Traumakinestä' 'Bexmarilimabiin'.

"Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that, on 16 April 2025, A&B (HK) Company Ltd (“A&B”) divested its entire shareholding of 3,559,893 ordinary shares representing approximately 3.40% of the Company’s issued share capital.

A&B (HK) Company Ltd, an investment and development company based in Hong Kong, initially invested in the Company in 2015. This investment was part of a strategic agreement involving Faron’s lead drug candidate, Traumakine®, which was developed for the treatment of moderate to severe acute respiratory distress syndrome (ARDS). As Faron’s focus is on the development of its lead asset, bexmarilimab, this strategic investment by A&B no longer serves its original purpose and as such, A&B sold its holding and created a significant increase in the liquidity of Faron’s shares in the market."

Kiitettävää tiedottamista yhtiöltä ja selkeyttää päätösten tekoa - mutta ei selitä kaikkea päiväkauppaan vaikuttamista.